ABSTRACT
Introduction Assessment of cognition and everyday function is essential in clinical trials for Alzheimer’s disease (AD). Two novel measures of cognition (No Practice Effects (NPE) cognitive battery and Miami Computerized Functional Assessment Scale (CFAS)) were designed to have robust psychometric properties and reduced practice and ceiling effects. This study aims to evaluate if the NPE and CFAS demonstrate stronger psychometric properties and reduced practice effects compared with established measures, including the Preclinical Alzheimer Cognitive Composite (PACC), Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Functional Activities Questionnaire (FAQ).
Methods This parallel group, four-site study will randomize 320 cognitively intact adults aged 60 to 85 years to novel or well-established measures of cognition and function. All participants will receive assessments at baseline (week 0), week 12, and week 52, as well as a brain MRI scan and Apolipoprotein E genetic test at study entry. Analyses will determine psychometric properties of the NPE and CFAS, compare the sensitivity of measures to AD risk markers, and identify cognitive domains within the NPE.
Discussion Practice effects have been a major limitation of Alzheimer’s disease clinical trials that typically assess cognitive changes over serial assessments. Detection of functional impairment in cognitively normal individuals with biomarkers for Alzheimer’s disease requires instruments sensitive to very subtle functional changes. This study is intended to support the validation of two new composite measures, the NPE battery and the CFAS, which may advance clinical testing of interventions for individuals across the spectrum of early stage Alzheimer’s disease.
Trial Registration NCT03900273
Competing Interest Statement
SAB and HRC report support from National Institute on Aging grants. HK, SL, AC, HA, AMR, and KI have none to report. AMB provides scientific consultation to Cognition Therapeutics, Inc and Regeneron Pharmaceuticals, Inc. AMB has served on an advisory board on early detection of Alzheimers disease for F. Hoffmann-La Roche, Ltd. DPD reports scientific advisory to Acadia, Genentech, and Sunovion. DPD has served on the DSMB for Green Valley. PDH reports grants from National Institute on Aging, during the conduct of the study. PDH reports grants from Takeda Pharma, grants from Stanley medical Research Foundation, other from iFunction, Inc., and personal fees from several pharmaceutical companies outside the current work. LSS reports grants and personal fees from several pharmaceutical companies and grants from Washington University/NIA DIAN-TU. TG receives royalties from VeraSci for use of the BACS in clinical trials.
Clinical Trial
NCT03900273
Funding Statement
This work is supported by the National Institute on Aging grant award R01AG051346.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is approved by the NYSPI IRB, the Feinstein Institute for Medical Research IRB, the University of Southern California Keck School of Medicine IRB, and the University of Miami Miller School of Medicine IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos